AbbVie (NYSE:ABBV), a United States-based biopharmaceutical company, has reported its financial results for the second quarter ended 30 June 2020, it was reported on Friday.
The firm posted net revenues of USD10.425bn in the second quarter of 2020, up 26.3% compared to the year-ago period of USD8.255bn.
The company reported a net earnings loss of USD739m, diluted loss per share of USD0.46 on a GAAP Basis and an adjusted diluted EPS of USD2.34 in Q2 2020 compared with net earnings loss of USD741m, diluted loss per share of USD0.49 on a GAAP Basis and an adjusted diluted EPS of USD2.26 in Q2 2019.
Quest Diagnostics declares quarterly dividend of of USD0.86 per share
BSF secures exclusive global commercialisation partnership for ETSYL
Saniona grants AstronauTx worldwide rights to neurological disease programme
Ridgetech reports financial results for fiscal year to March 2026
West Pharmaceutical Services declares quarterly dividend of USD0.22 per share
MedPal AI acquires eMARx to expand digital care home platform
Valerio Therapeutics signs R&D collaboration with Abivax and outlines pipeline milestones
Labcorp declares quarterly dividend of USD0.72 per share
Aptamer Group launches Optimer-based Ebola diagnostic programme
SK bioscience to lead Gates Foundation-funded ROTOR project
Nona Biosciences and Lonza collaborate on antibody-based BBB-crossing technology for CNS diseases
Lilly declares Q3 2026 dividend
Abbott declares quarterly dividend of USD0.63 per share
Gilead Sciences mobilises remdesivir donation to support Ebola response in Uganda